Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia: Experiences from the randomized, controlled SOCOGAMI trial

BACKGROUND: Empagliflozin reduces the risk of cardiovascular disease (CVD) in patients with type 2 diabetes (T2DM) and high cardiovascular risk via mechanisms which have not been fully explained. The mechanisms of such benefit have not been fully understood, and whether empagliflozin can be safely a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fortin, Elena, Lundin, Magnus, Mellbin, Linda, Norhammar, Anna, Näsman, Per, Smetana, Stina, Sörensson, Peder, Ferrannini, Ele, Rydén, Lars, Ferrannini, Giulia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422806/
https://www.ncbi.nlm.nih.gov/pubmed/37568149
http://dx.doi.org/10.1186/s12933-023-01950-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422806/
https://www.ncbi.nlm.nih.gov/pubmed/37568149
http://dx.doi.org/10.1186/s12933-023-01950-0

Ejemplares similares